Inovio Pharmaceuticals, Inc. (NASDAQ:INO) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 8,603,835 shares, a decline of 20.5% from the July 14th total of 10,821,529 shares. Currently, 10.2% of the company’s shares are short sold. Based on an average daily volume of 3,606,177 shares, the short-interest ratio is presently 2.4 days.

A number of equities analysts have recently commented on INO shares. Nomura reiterated a “buy” rating and set a $40.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 7th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a report on Tuesday, July 11th. Finally, Jefferies Group LLC reiterated a “neutral” rating and set a $38.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $20.78.

Inovio Pharmaceuticals (NASDAQ:INO) opened at 5.56 on Friday. Inovio Pharmaceuticals has a 12-month low of $5.32 and a 12-month high of $9.86. The firm’s market cap is $501.66 million. The company has a 50-day moving average of $6.81 and a 200 day moving average of $6.81.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. During the same period last year, the company posted ($0.26) EPS. The company’s quarterly revenue was up 229.2% compared to the same quarter last year. Equities analysts expect that Inovio Pharmaceuticals will post ($0.93) EPS for the current fiscal year.

In other news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total transaction of $64,000.00. Following the transaction, the director now owns 740,956 shares in the company, valued at $5,927,648. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.60% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of INO. PNC Financial Services Group Inc. boosted its stake in Inovio Pharmaceuticals by 5.0% in the second quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in Inovio Pharmaceuticals during the second quarter valued at approximately $171,000. Bank of America Corp DE boosted its stake in Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares in the last quarter. OxFORD Asset Management LLP bought a new stake in Inovio Pharmaceuticals during the second quarter valued at approximately $194,000. Finally, UBS Asset Management Americas Inc. boosted its stake in Inovio Pharmaceuticals by 0.4% in the second quarter. UBS Asset Management Americas Inc. now owns 25,710 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 92 shares in the last quarter. 22.92% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Inovio Pharmaceuticals, Inc. (INO) Short Interest Update” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/08/12/inovio-pharmaceuticals-inc-ino-short-interest-update.html.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.